Page last updated: 2024-11-05

troglitazone and Shock

troglitazone has been researched along with Shock in 1 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Shock: A pathological condition manifested by failure to perfuse or oxygenate vital organs.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Maggi, LB1
Sadeghi, H1
Weigand, C1
Scarim, AL1
Heitmeier, MR1
Corbett, JA1

Other Studies

1 other study available for troglitazone and Shock

ArticleYear
Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression.
    Diabetes, 2000, Volume: 49, Issue:3

    Topics: Animals; Anti-Inflammatory Agents; Cell Line; Chromans; Cytokines; Hot Temperature; Interferon-gamma

2000